Janon

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

Retrieved on: 
Thursday, August 31, 2023
Pain, Patent, Diabetic neuropathy, Janon, American Society of Interventional Pain Physicians, United States patent law, Chronic pain, Patient, Conference, Ohio Society of New York, Pharmaceutical industry

LAS VEGAS, Aug. 31, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25th Annual Global Investment Conference in New York City. JanOne's Chief Medical Officer, Dr. Amol Soin, will appear via recorded video and attend the conference in person to represent the company's mission and progress.

Key Points: 
  • LAS VEGAS, Aug. 31, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25th Annual Global Investment Conference in New York City.
  • JanOne's Chief Medical Officer, Dr. Amol Soin, will appear via recorded video and attend the conference in person to represent the company's mission and progress.
  • Dr. Soin's virtual presentation will be shown September 11 — 13th and will be accessible on the JanOne.com website in subsequent days.
  • This week, on August 29, JanOne announced that it had received a US Patent for its use of its novel formulation of low-dose naltrexone, Jan123, to treat chronic pain.

JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

Retrieved on: 
Tuesday, August 29, 2023
Hypersensitivity, Patent, Narcotic, CPRS, United States patent law, Endorphins, CRPS, Naltrexone, Today, Language, Pain, Report, Patient, Enkephalin, Janon, System, FDA, Chronic pain, Disease, Pharmaceutical industry

LAS VEGAS, Aug. 29, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a US patent for its innovative formulation of low-dose naltrexone, Jan123, for treating pain.

Key Points: 
  • Jan123 is being developed to treat complex regional pain syndrome (CRPS), a rare and often life-altering condition characterized by severe pain and hypersensitivity to touch.
  • "Today, patients with complex regional pain syndrome must resort to long-term opioid and narcotics for relief," Isaac said.
  • Dr. Amol Soin, the inventor of Jan123 and its novel uses, expressed great satisfaction with the US Patent Office's action.
  • "All in all," CEO Isaac concluded, "this patent approval is an important milestone in our company's brief history—and a welcome confirmation of our strategic vision."

JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

Retrieved on: 
Friday, August 25, 2023
II, LAS, Pain, Ohio Society of New York, Diabetic neuropathy, Janon, Research, Patient, Physician, American Society of Interventional Pain Physicians, Consumer electronics, Pharmaceutical industry

LAS VEGAS, Aug. 25, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, has won a prestigious "Best Abstract" award for reporting that JanOne's treatment for diabetic neuropathy showed both effectiveness against pain and potential to improve nerve function.

Key Points: 
  • Abstract explained Jan101's statistically significant reduction in pain and improvement in nerve conduction velocity in prior Phase II study.
  • The abstract was presented at the annual meeting of the Ohio Society of Interventional Pain Physicians (OHSIPP), one of the nation's largest regional pain management meetings typically attracting 300 physicians from around the country.
  • The JanOne abstract, selected as one of the top three, analyzed prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.
  • "Winning this award is a gratifying validation by independent peers of the work we are doing," Dr. Soin said.

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting

Retrieved on: 
Friday, August 18, 2023
Diabetic neuropathy, Extremities, Ohio Society of New York, JAN, Risk, Physician, PAD, Hypoesthesia, CRPS, American Society of Interventional Pain Physicians, LAS, Patient, Security (finance), FDA, Pharmaceutical industry, Pain, Janon

LAS VEGAS, Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.

Key Points: 
  • JAN101 Showed Statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity in Prior Phase II study.
  • LAS VEGAS, Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.
  • The Ohio Society of Interventional Pain Physicians annual meeting is a large regional pain management meeting from August 17 – 20th that draws attendance from physicians across the US.
  • Diabetic neuropathy is an often-debilitating condition that is on the rise in the USA characterized by burning pain and numbness typically in the extremities.

JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

Retrieved on: 
Wednesday, June 28, 2023
Risk, Clinical trial, PAD, Hope, CRPS, Patent, Patient, Security (finance), FDA, Chronic pain, Netflix, Complex regional pain syndrome, Pharmaceutical industry, Peripheral artery disease, Janon

LAS VEGAS, June 28, 2023 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a biopharmaceutical company that is developing multiple drugs to treat chronic diseases like Peripheral Artery Disease (PAD) and Complex Regional Pain Syndrome (CRPS), has just filed an international patent application for methods of using low dose naltrexone to treat chronic pain.

Key Points: 
  • LAS VEGAS, June 28, 2023 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a biopharmaceutical company that is developing multiple drugs to treat chronic diseases like Peripheral Artery Disease (PAD) and Complex Regional Pain Syndrome (CRPS), has just filed an international patent application for methods of using low dose naltrexone to treat chronic pain.
  • JanOne is developing Jan123 (a novel formulation of low dose naltrexone) to treat CRPS, an orphan disease with no current FDA-approved treatments.
  • CRPS leaves patients in debilitating pain and suffering and, as a result, oftentimes patients resort to opioid pain medications.
  • "This international patent application is part of our strategy to help patients around the world who are suffering from this debilitating disease.

JanOne Completes Pre-IND Meeting with FDA on Jan123

Retrieved on: 
Tuesday, April 18, 2023
Opioid, JAN, Risk, CMC, PAD, United States drug overdose death rates and totals over time, Pharmacokinetics, CRPS, Naltrexone, Pain, Patient, Chemistry, Pain management, Control, Security (finance), FDA, Complex regional pain syndrome, Pharmaceutical industry, Janon

LAS VEGAS, April 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical innovator specializing in non-addicting painkillers and new treatments for the causes of pain, has completed a successful pre-IND meeting with the FDA regarding Jan123. Jan123 is the company's unique oral delivery of low dose naltrexone formulated to treat complex regional pain syndrome, an orphan disease of severe, debilitating impact.

Key Points: 
  • LAS VEGAS, April 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical innovator specializing in non-addicting painkillers and new treatments for the causes of pain, has completed a successful pre-IND meeting with the FDA regarding Jan123.
  • The Pre-IND meeting with the FDA produced a path toward formal drug application.
  • The agency's feedback will be used to move Jan123 toward a New Drug Application under a 505-b2 designation.
  • JanOne CEO Tony Isaac noted that Jan123 is one of two late-stage innovative therapies for pain management developed by JanOne.

JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023

Retrieved on: 
Thursday, April 13, 2023
Spine, Diabetic neuropathy, JAN, Risk, PAD, CRPS, Pain, Patient, Physician, Complex regional pain syndrome, Peripheral artery disease, Pain management, Security (finance), FDA, Chronic pain, Appalachia, Pharmaceutical industry, Janon

The Appalachian Spine and Pain Meeting is a forum attended mostly by pain management physicians to learn and discuss new and innovative treatments.

Key Points: 
  • The Appalachian Spine and Pain Meeting is a forum attended mostly by pain management physicians to learn and discuss new and innovative treatments.
  • JanOne is working to develop multiple medications to help treat pain without addiction.
  • "The opioid crisis really impacted this country and we realized what is needed are new options to treat pain without opioids.
  • We look forward to developing these products so doctors have the tools they need to treat pain without addiction", noted Tony Isaac CEO of JanOne.

JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team

Retrieved on: 
Thursday, March 23, 2023
Diabetic neuropathy, US, HIV, Triclonella sequella, JAN, Risk, PAD, International, CRPS, Doctor of Philosophy, The Immune Response Corporation, LAS, Pain, Peripheral artery disease, Running, Pain management, Security (finance), Neuro, FDA, Chronic pain, Consultant, Pharmaceutical industry, Management, Bonfiglio, Janon

LAS VEGAS, March 23, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced the hiring of John N. Bonfiglio, PhD, as interim president of its JanOne Biotech subsidiary. JanOne Biotech focuses on pain management for diabetic neuropathy, Peripheral Artery Disease (PAD), and other chronic pain conditions using innovative treatments developed by JanOne Inc.

Key Points: 
  • Dr. Bonfiglio is a veteran leader in the biotech industry with a track record of raising capital, building start-ups and excelling in C-suite roles.
  • After spending his early career at Allergan Pharmaceuticals and Baxter HealthCare, he turned to discovering, promoting and leading smaller biotech ventures.
  • Currently he is a board member for Avipero and executive board member for Sequella, a US- based biotech company.
  • Dr. Bonfiglio expressed his "goals for collaborating with the well-respected scientific team at JanOne."

JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management

Retrieved on: 
Thursday, January 26, 2023
Therapy, Risk, LAS, Anesthesiology, Drug, Pain, Security (finance), PAD, Rush University, Korea Disease Control and Prevention Agency, CRPS, Drug development, Nasdaq MarketSite, Pain management, FDA, Research, Physician, Anesthesia, JAN, Acquisition, Opioid, Doctor of Philosophy, Dietary supplement, Pharmaceutical industry, Janon

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), which develops treatments for underlying causes of severe pain and brings to market drugs that relieve pain without the risk of addiction, held meetings at New York's Nasdaq MarketSite to review strategic plans and to facilitate integration of recently-acquired Soin Therapeutics.

Key Points: 
  • JanOne was founded to tackle the society-wide crisis of opioid abuse by discovering non-addictive, non-sedating alternative treatments for pain.
  • In its ongoing response to the crisis, JanOne has two late-stage clinical drug development programs: One is low-dose naltrexone (renamed JAN 123) that treats complex regional pain syndrome and was developed by Soin Therapeutics.
  • He is among the nation's leading research and clinical specialists in pain management.
  • Starting as a resident in anesthesiology at Chicago's Rush University, he has actively engaged in research in pain management and anesthesia.

SPYR, Inc. CEO Comments on the Fiscal Year End 2022

Retrieved on: 
Tuesday, January 3, 2023
OTCQB, Internet of things, Patent, IOT, Janon

CEO Tim Matula, noted: “I first want to thank our shareholders for sharing our vision this year.

Key Points: 
  • CEO Tim Matula, noted: “I first want to thank our shareholders for sharing our vision this year.
  • The year 2022 was eventful for SPYR.
  • On December 20, 2022, we wound down and dissolved Applied Magix in Nevada and now we are 100% focused on growing our GeoTraq business, products and services.
  • We look forward to the new year with enthusiasm as we concentrate all of our efforts on GeoTraq.